Skip to main content
Log in

New developments and directions in the clinical application of the echinocandins

  • Review Article
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

The echinocandins—caspofungin, anidulafungin and micafungin—are semi-synthetic cyclic hexapeptide antimicrobial agents with modified N-linked acyl lipid side chains which anchor the compounds to the phospholipid bilayer of the fungal cell membrane, thereby inhibiting synthesis of fungal cell wall glucan. Over the last 10 years, echinocandins have become the first-line antifungal treatment of candidaemia and other forms of invasive candidiasis (IC). Echinocandins are generally well tolerated, but their use is limited by their requirement for daily intravenous dosing, lack of oral formulation and limited spectrum. In critically ill patients, it is also recognised that achievement of their pharmacokinetic/pharmacodynamic targets shows large inter-individual variability. As a drug class, they are safe to use and are associated with few adverse reactions and few drug–drug interactions of significance. Recent discovery of their ability to prevent and treat Candida biofilm formation particularly in the presence of invasive medical devices and also their ability to penetrate into mucosal surfaces such as vulvovaginal candidiasis has opened up new opportunities for research into their drug delivery. New dosing intervals are being explored to allow less frequent intravenous dosing in the ambulatory setting, and a new long-acting echinocandin, CD101, is being developed for weekly and topical administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aguilar-Zapata D, Petraitiene R, Petraitis V (2015) Echinocandins: the expanding antifungal armamentarium. Clin Infect Dis 61(Suppl 6):S604–S611

    Article  CAS  PubMed  Google Scholar 

  • Alothman AF, Al-Musawi T, Al-Abdely HM, Salman JA, Almaslamani M, Yared N et al (2014) Clinical practice guidelines for the management of invasive Candida infections in adults in the Middle East region: expert panel recommendations. J Infect Public Health 7(1):6–19

    Article  PubMed  Google Scholar 

  • Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A (2010) In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54(6):2497–2506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR et al (2002) In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 46(11):3591–3596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bohn JB (1995) JN. (1-3)-b-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr Polym 28:3–14

    Article  CAS  Google Scholar 

  • Brown GD, Gordon S (2003) Fungal beta-glucans and mammalian immunity. Immunity 19(3):311–315

    Article  CAS  PubMed  Google Scholar 

  • Castanheira M, Messer SA, Rhomberg PR, Pfaller MA (2016) Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). Diagn Microbiol Infect Dis 85(2):200–204

    Article  CAS  PubMed  Google Scholar 

  • Chen SC, Slavin MA, Sorrell TC (2011) Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71(1):11–41

    Article  PubMed  Google Scholar 

  • Chen SC, Sorrell TC, Chang CC, Paige EK, Bryant PA, Slavin MA (2014) Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Intern Med J 44(12b):1315–1332

    Article  CAS  PubMed  Google Scholar 

  • Cleary JD, Stover KR (2015) Antifungal-associated drug-induced cardiac disease. Clin Infect Dis 61(Suppl 6):S662–S668

    Article  CAS  PubMed  Google Scholar 

  • Coad B, Lamont-Friedrich SJ, Gwynne L, Jasieniak M, Griesser SS, Traven A, Peleg AY, Griessera HJ (2015) Surface coatings with covalently attached caspofungin are effective in eliminating fungal pathogens. J Mater Chem B 3:8

    Article  Google Scholar 

  • Coad BR, Griesser HJ, Peleg AY, Traven A (2016) Anti-infective surface coatings: design and therapeutic promise against device-associated infections. PLoS Pathog 12(6):e1005598

    Article  PubMed  PubMed Central  Google Scholar 

  • Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al (2007) Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359

    Article  CAS  PubMed  Google Scholar 

  • Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):19–37

    Article  CAS  PubMed  Google Scholar 

  • Cushion MAA, Lynch K, Linke MJ (2016) Prevention of pneumocystis pneumonia (PCP) by the novel echinocandin, CD101. ASM Microbes 2016; June 16–20, Boston, MA2016

  • Denning DW (2003) Echinocandin antifungal drugs. Lancet 362(9390):1142–1151

    Article  CAS  PubMed  Google Scholar 

  • Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C et al (2006) Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53(5):337–349

    Article  PubMed  Google Scholar 

  • Fink M, Zerlauth U, Kaulfersch C, Rab A, Alberer D, Preiss P et al (2013) A severe case of haemodynamic instability during anidulafungin administration. J Clin Pharm Ther 38(3):241–242

    Article  CAS  PubMed  Google Scholar 

  • Fuchs BB, Li Y, Li D, Johnston T, Hendricks G, Li G et al (2016) Micafungin elicits an immunomodulatory effect in galleria mellonella and mice. Mycopathologia 181(1–2):17–25

    Article  CAS  PubMed  Google Scholar 

  • Garcia R, Botet J, Rodriguez-Pena JM, Bermejo C, Ribas JC, Revuelta JL et al (2015) Genomic profiling of fungal cell wall-interfering compounds: identification of a common gene signature. BMC Genom 16:683

    Article  Google Scholar 

  • Goto N, Hara T, Tsurumi H, Ogawa K, Kitagawa J, Kanemura N et al (2010) Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies. Am J Hematol 85(11):872–876

    Article  CAS  PubMed  Google Scholar 

  • Gumbo T (2015) Single or 2-dose micafungin regimen for treatment of invasive candidiasis: therapia sterilisans magna! Clin Infect Dis 61(Suppl 6):S635–S642

    Article  PubMed  Google Scholar 

  • Hanson KE, Pfeiffer CD, Lease ED, Balch AH, Zaas AK, Perfect JR et al (2012) Beta-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS ONE 7(8):e42282

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hector RF (1993) Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 6(1):1–21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hector RF, Bierer DE (2011) New beta-glucan inhibitors as antifungal drugs. Expert Opin Ther Pat 21(10):1597–1610

    Article  CAS  PubMed  Google Scholar 

  • Hindahl CB, Wilson JW (2012) Flash pulmonary oedema during anidulafungin administration. J Clin Pharm Ther 37(4):491–493

    Article  CAS  PubMed  Google Scholar 

  • Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M et al (2008) Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 88(5):588–595

    Article  CAS  PubMed  Google Scholar 

  • Jimenez-Ortigosa C, Paderu P, Motyl MR, Perlin DS (2014) Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. Antimicrob Agents Chemother 58(2):1248–1251

    Article  PubMed  PubMed Central  Google Scholar 

  • Katragkou A, Roilides E, Walsh TJ (2015) Role of echinocandins in fungal biofilm-related disease: vascular catheter-related infections, immunomodulation, and mucosal surfaces. Clin Infect Dis 61(Suppl 6):S622–S629

    Article  CAS  PubMed  Google Scholar 

  • Knitsch W, Vincent JL, Utzolino S, Francois B, Dinya T, Dimopoulos G et al (2015) A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis 61(11):1671–1678

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R et al (2010) Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 61(5):410–418

    Article  PubMed  Google Scholar 

  • Kojic EM, Darouiche RO (2004) Candida infections of medical devices. Clin Microbiol Rev 17(2):255–267

    Article  PubMed  PubMed Central  Google Scholar 

  • Koselny KGJ, DiDone L, Glazier V, Krysan K (2016) AR-12, an Antifungal Derivative of Celecoxib, is a Fungal acetyl CoA synthetase inhibitor and modulates the azole and echinocandin susceptibility of resistant candida species. In: 13th ASM Conference on Candida and Candidiasis; April 13–17, 2016; Seattle, WA2016

  • Koselny K, Green J, Favazzo L, Glazier VE, DiDone L, Ransford S et al (2016b) Antitumor/antifungal celecoxib derivative AR-12 is a non-nucleoside inhibitor of the ANL-family adenylating enzyme Acetyl CoA synthetase. ACS Infect Dis. 2(4):268–280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kucharikova S, Gerits E, De Brucker K, Braem A, Ceh K, Majdic G et al (2016) Covalent immobilization of antimicrobial agents on titanium prevents Staphylococcus aureus and Candida albicans colonization and biofilm formation. J Antimicrob Chemother 71(4):936–945

    Article  CAS  PubMed  Google Scholar 

  • Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D et al (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369(9572):1519–1527

    Article  CAS  PubMed  Google Scholar 

  • Lamoth F, Alexander BD (2015) Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates. Antimicrob Agents Chemother 59(7):4308–4311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee KK, Maccallum DM, Jacobsen MD, Walker LA, Odds FC, Gow NA et al (2012) Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother 56(1):208–217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lempers VJ, Schouten JA, Hunfeld NG, Colbers A, van Leeuwen HJ, Burger DM et al (2015) Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother 59(8):4403–4409

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lepak AJ, Marchillo K, Andes DR (2015) Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother 59(2):1265–1272

    Article  PubMed  PubMed Central  Google Scholar 

  • Lichtenstern C, Wolff M, Arens C, Klie F, Majeed RW, Henrich M et al (2013) Cardiac effects of echinocandin preparations—three case reports. J Clin Pharm Ther 38(5):429–431

    Article  CAS  PubMed  Google Scholar 

  • Locke JB, Almaguer AL, Zuill DE, Bartizal K (2016) Characterization of in vitro resistance development to the novel echinocandin CD101 in Candida species. Antimicrob Agents Chemother 60(10):6100–6107. doi:10.1128/AAC.00620-16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lortholary O, Petrikkos G, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clin Microbiol Infect 18(Suppl 7):68–77

    Article  CAS  PubMed  Google Scholar 

  • Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH et al (2006) Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107(12):2888–2897

    Article  CAS  PubMed  Google Scholar 

  • Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS et al (2010) A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 29(5):415–420

    Article  PubMed  Google Scholar 

  • Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA et al (2015) Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 162(2):81–89

    Article  PubMed  Google Scholar 

  • Miesel LL, Lin KY, Chien JC, Hsieh ML, Ong V, Bartizal, K (2016) Efficacy of a novel echinocandin, CD101, in a mouse model of azole-resistant disseminated candidiasis. ASM Microbes 2016; June 16–20, Boston, MA2016

  • Mizuno H, Sawa M, Yanada M, Shirahata M, Watanabe M, Kato T et al (2013) Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study. Int J Hematol 98(2):231–236

    Article  CAS  PubMed  Google Scholar 

  • Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25):2020–2029

    Article  CAS  PubMed  Google Scholar 

  • Muilwijk EW, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Colbers A et al (2014) Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother 69(12):3294–3299

    Article  CAS  PubMed  Google Scholar 

  • Muilwijk EW, Lempers VJ, Burger DM, Warris A, Pickkers P, Aarnoutse RE et al (2015) Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Rev Anti Infect Ther. 13(6):799–815

    Article  CAS  PubMed  Google Scholar 

  • Neofytos D, Huang YT, Cheng K, Cohen N, Perales MA, Barker J et al (2015) Safety and efficacy of intermittent intravenous administration of high-dose micafungin. Clin Infect Dis 61(Suppl 6):S652–S661

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Neoh CF, Liew D, Slavin M, Marriott D, Chen SC, Morrissey O et al (2011) Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. J Antimicrob Chemother 66(8):1906–1915

    Article  CAS  PubMed  Google Scholar 

  • Ong VB, Bartizal K, Hughes D, Miesel L, Lin W, Webb J, Chen A (2016) Optimization of CD101 formulation against Candida albicans in a rat model of vulvovaginal candidiasis (VVC). In: ASM Microbes 2016; June 1–20, Boston, MA2016

  • Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis [Aug 8, 2016]. ClinicalTrials.gov]. https://clinicaltrials.gov/ct2/show/NCT02244606

  • Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA et al (2014) MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 58(9):1219–1226

    Article  CAS  PubMed  Google Scholar 

  • Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al (2016) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62(4):e1–e50

    Article  PubMed  Google Scholar 

  • Peleg AY, Hogan DA, Mylonakis E (2010) Medically important bacterial-fungal interactions. Nat Rev Microbiol 8(5):340–349

    Article  CAS  PubMed  Google Scholar 

  • Perlin DS (2015) Echinocandin resistance in Candida. Clin Infect Dis 61(Suppl 6):S612–S617

    Article  PubMed  PubMed Central  Google Scholar 

  • Perlin DS (2016) CD101, A novel, long-acting echinocandin provides high plasma exposure that expands in vivo efficacy. In: 13th ASM Conference on Candida and Candidiasis; April 13–17, Seattle, WA2016

  • Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M (2016) Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. J Antimicrob Chemother 71(10):2868–2873. doi:10.1093/jac/dkw214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M (2013a) Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother 68(4):858–863

    Article  CAS  PubMed  Google Scholar 

  • Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M (2013b) In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. Antimicrob Agents Chemother 57(2):1065–1068

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pfaller MA, Rhomberg PR, Messer SA, Castanheira M (2015) In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. Diagn Microbiol Infect Dis 81(4):259–263

    Article  CAS  PubMed  Google Scholar 

  • Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C (2015) Antifungal drugs during pregnancy: an updated review. J Antimicrob Chemother 70(1):14–22

    Article  CAS  PubMed  Google Scholar 

  • Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T et al (2008) Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 27(9):820–826

    Article  PubMed  Google Scholar 

  • Ramage G, VandeWalle K, Bachmann SP, Wickes BL, Lopez-Ribot JL (2002) In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 46(11):3634–3636

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ramos-Martin V, O’Connor O, Hope W (2015) Clinical pharmacology of antifungal agents in pediatrics: children are not small adults. Curr Opin Pharmacol 24:128–134

    Article  CAS  PubMed  Google Scholar 

  • Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356(24):2472–2482

    Article  CAS  PubMed  Google Scholar 

  • Saliba F, Pascher A, Cointault O, Laterre PF, Cervera C, De Waele JJ et al (2015) Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis 60(7):997–1006

    CAS  PubMed  Google Scholar 

  • Sandison T, Ong V, Lee J, Thye D (2017) Safety and Pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother 61(2). doi:10.1128/AAC.01627-16

  • Schneeweiss S, Carver PL, Datta K, Galar A, Johnson MD, Johnson MG et al (2016) Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study. J Antimicrob Chemother 71(10):2938–2944. doi:10.1093/jac/dkw225

    Article  PubMed  Google Scholar 

  • Shah PJ, Sundareshan V, Miller B, Bergman SJ (2016) Micafungin and a case of polymorphic ventricular tachycardia. J Clin Pharm Ther 41(3):362–364

    Article  CAS  PubMed  Google Scholar 

  • Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R (2006) Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J Infect Dis 194(5):710–713

    Article  CAS  PubMed  Google Scholar 

  • Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K et al (2006) Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81(3):320–326

    Article  CAS  PubMed  Google Scholar 

  • Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ et al (2015) Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Crit Care 19:33

    Article  PubMed  PubMed Central  Google Scholar 

  • Steinbach WJ, Lamoth F, Juvvadi PR (2015) Potential microbiological effects of higher dosing of echinocandins. Clin Infect Dis 61(Suppl 6):S669–S677

    Article  CAS  PubMed  Google Scholar 

  • Stover KR, Farley JM, Kyle PB, Cleary JD (2014) Cardiac toxicity of some echinocandin antifungals. Expert Opin Drug Saf 13(1):5–14

    Article  CAS  PubMed  Google Scholar 

  • Timsit JF, Azoulay E, Cornet M, Gangneux JP, Jullien V, Vesin A et al (2013) EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials 14:399

    Article  PubMed  PubMed Central  Google Scholar 

  • Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18(Suppl 7):53–67

    Article  CAS  PubMed  Google Scholar 

  • Valiante V, Monteiro MC, Martin J, Altwasser R, El Aouad N, Gonzalez I et al (2015) Hitting the caspofungin salvage pathway of human-pathogenic fungi with the novel lasso peptide humidimycin (MDN-0010). Antimicrob Agents Chemother 59(9):5145–5153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs ZG et al (2015) Epidemiology and risk factors for echinocandin nonsusceptible candida glabrata bloodstream infections: data from a large multisite population-based Candidemia Surveillance Program, 2008–2014. Open Forum Infect Dis 2(4):ofv163

    Article  PubMed  PubMed Central  Google Scholar 

  • van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407–1416

    Article  PubMed  Google Scholar 

  • Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA (2008) Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog 4(4):e1000040

    Article  PubMed  PubMed Central  Google Scholar 

  • Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351(14):1391–1402

    Article  CAS  PubMed  Google Scholar 

  • Wheeler RT, Fink GR (2006) A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2(4):e35

    Article  PubMed  PubMed Central  Google Scholar 

  • Winston DJ, Limaye AP, Pelletier S, Safdar N, Morris MI, Meneses K et al (2014) Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant 14(12):2758–2764

    Article  CAS  PubMed  Google Scholar 

  • Zhao Y, Nagasaki Y, Kordalewska M, Press EG, Shields RK, Nguyen MH et al (2016) Rapid detection of FKS-associated echinocandin resistance in Candida glabrata. Antimicrob Agents Chemother 60(11):6573–6577. doi:10.1128/AAC.01574-16

Download references

Acknowledgements

CCC is an Australian National Health and Medical Research Council (NHMRC) Early Career Fellow (1092160).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. C.-A. Chen.

Ethics declarations

Conflict of interest

All authors declared that there is no conflict of interest. SC-AC and MAS are members of the Antifungal Advisory Boards of Gilead Sciences Inc., Merck, and Pfizer, Australia, and have received untied investigator-initiated grants from Pfizer Australia, Gilead Sciences and Merck.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, C.C., Slavin, M.A. & Chen, S.CA. New developments and directions in the clinical application of the echinocandins. Arch Toxicol 91, 1613–1621 (2017). https://doi.org/10.1007/s00204-016-1916-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-016-1916-3

Keywords

Navigation